Evolent Health Reports $496.2 Million Revenue in Q1 2026, Operating Loss Increases

Evolent Health, Inc. reported a revenue of $496.2 million for the first quarter of 2026, marking a 2.6% increase from $483.6 million in the same period of 2025. The growth was primarily driven by a new Performance Suite contract that contributed $83 million, although this was partially offset by a $58 million reduction in revenue following the sale of Evolent Care Partners and a $17 million decline in Medicare memberships. The company recorded an operating loss of $10.6 million, a significant increase from the $1.6 million loss reported in the prior year, largely due to rising costs associated with claims and operational expenses.

Total expenses for the quarter rose to $506.8 million, up from $485.3 million in the previous year. The cost of revenue increased by 8.2% to $412.5 million, driven by higher claims costs, which were influenced by the new Performance Suite contracts. Selling, general, and administrative expenses decreased by 7.1% to $72.8 million, attributed to lower personnel costs and reduced professional fees. The company’s medical expense ratio (MER) for its specialty care management services solution was reported at 93.3%, up from 68.0% in the previous year, indicating increased costs relative to revenue.

Evolent Health's operational metrics showed a decline in average lives on the platform, which fell to 6,078 from 6,486 year-over-year. The average per member per month (PMPM) fee for the Performance Suite increased to $17.73, compared to $15.57 in the prior year, reflecting the impact of new contracts. The company also reported a net loss attributable to common shareholders of $26.6 million, a decrease from a loss of $72.3 million in the same quarter of 2025.

In terms of strategic developments, Evolent Health continues to navigate a challenging regulatory environment, particularly following the enactment of the One Big Beautiful Bill Act, which may lead to reduced membership in Medicaid and ACA Health Exchanges. The company has indicated that it believes its current cash and cash equivalents, totaling $142 million, will be sufficient to meet its operational needs for at least the next twelve months. Evolent Health is also focused on expanding its market presence and enhancing its service offerings, although it acknowledges the potential for ongoing volatility in the healthcare landscape.

Looking ahead, Evolent Health anticipates that the dynamics of rising medical claims costs and regulatory changes could continue to impact its financial performance. The company remains committed to its strategy of providing integrated care solutions while managing operational costs effectively. As it moves forward, Evolent Health will continue to assess its market position and adapt to the evolving healthcare environment.